Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer: Frontiers in Immunology

S. Ottonello, C. Genova, I. Cossu, V. Fontana, E. Rijavec, G. Rossi, F. Biello, M.G. Dal Bello, M. Tagliamento, A. Alama, S. Coco, S. Boccardo, I. Vanni, G. Ferlazzo, L. Moretta, F. Grossi, M.C. Mingari, P. Carrega, G. Pietra

Research output: Contribution to journalArticle

Original languageEnglish
Article number125
JournalFront. Immunol.
Volume11
DOIs
Publication statusPublished - 2020

Keywords

  • biomarkers
  • immune checkpoint
  • nivolumab
  • non-small-cell lung cancer
  • PD-1
  • peripheral blood
  • CD3 antigen
  • CD4 antigen
  • CD8 antigen
  • prednisone
  • programmed death 1 ligand 1
  • advanced cancer
  • aged
  • Article
  • B lymphocyte subpopulation
  • blood sampling
  • cancer diagnosis
  • CD4+ T lymphocyte
  • CD8+ T lymphocyte
  • clinical outcome
  • cohort analysis
  • controlled study
  • corticosteroid therapy
  • disease association
  • female
  • flow cytometry
  • human
  • innate immunity
  • major clinical study
  • male
  • natural killer cell
  • non small cell lung cancer
  • overall survival
  • peripheral blood mononuclear cell
  • peripheral lymphocyte
  • progression free survival
  • protein expression
  • treatment response

Cite this